Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

Background: Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report the first clinical trial on the tolerability, pharmacokinetics and pharmacodynamics of different doses of vicagrel, and comparison with clopidogr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Pharmacol
Главные авторы: Li, Xiaojiao, Liu, Cai, Zhu, Xiaoxue, Wei, Haijing, Zhang, Hong, Chen, Hong, Chen, Guiling, Yang, Deming, Sun, Hongbin, Shen, Zhenwei, Zhang, Yifan, Li, Wei, Yang, Jin, Liu, Yongqiang, Lai, Xiaojuan, Gong, Yanchun, Liu, Xuefang, Li, Yongguo, Zhong, Dafang, Niu, Junqi, Liu, Bin, Ding, Yanhua
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2018
Предметы:
Pharmacology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6019484/
https://ncbi.nlm.nih.gov/pubmed/29973877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00643
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы